Oppenheimer Downgrades Sage Therapeutics to Perform
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has downgraded Sage Therapeutics from Outperform to Perform.
August 07, 2023 | 8:58 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has been downgraded by Oppenheimer from Outperform to Perform.
Analyst ratings often have a direct impact on stock prices. A downgrade from Outperform to Perform suggests that the analyst believes the stock will not outperform the market anymore, which could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100